AU745302B2 - Method of treatment for premature rupture of membranes in pregnancy (PROM) - Google Patents
Method of treatment for premature rupture of membranes in pregnancy (PROM) Download PDFInfo
- Publication number
- AU745302B2 AU745302B2 AU40948/99A AU4094899A AU745302B2 AU 745302 B2 AU745302 B2 AU 745302B2 AU 40948/99 A AU40948/99 A AU 40948/99A AU 4094899 A AU4094899 A AU 4094899A AU 745302 B2 AU745302 B2 AU 745302B2
- Authority
- AU
- Australia
- Prior art keywords
- fluent
- cervix
- fluent material
- seal
- uterine wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 120
- 238000011282 treatment Methods 0.000 title claims description 52
- 230000035935 pregnancy Effects 0.000 title claims description 41
- 206010036603 Premature rupture of membranes Diseases 0.000 title description 3
- 239000000463 material Substances 0.000 claims description 176
- 210000003679 cervix uteri Anatomy 0.000 claims description 78
- 210000001691 amnion Anatomy 0.000 claims description 63
- 210000001519 tissue Anatomy 0.000 claims description 61
- 210000004381 amniotic fluid Anatomy 0.000 claims description 52
- 210000004379 membrane Anatomy 0.000 claims description 49
- 239000012528 membrane Substances 0.000 claims description 49
- 230000004888 barrier function Effects 0.000 claims description 33
- 239000000499 gel Substances 0.000 claims description 32
- 239000000017 hydrogel Substances 0.000 claims description 29
- 229920000642 polymer Polymers 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 238000007789 sealing Methods 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000004132 cross linking Methods 0.000 claims description 12
- 230000002028 premature Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 210000001215 vagina Anatomy 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 230000001605 fetal effect Effects 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000002847 Surgical Wound Diseases 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 230000002269 spontaneous effect Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920000193 polymethacrylate Polymers 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- -1 bacteriostats Substances 0.000 claims description 3
- 238000005354 coacervation Methods 0.000 claims description 3
- 238000001879 gelation Methods 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 2
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- 241001312219 Amorphophallus konjac Species 0.000 claims description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920002581 Glucomannan Polymers 0.000 claims description 2
- 229920002752 Konjac Polymers 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229940030225 antihemorrhagics Drugs 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 150000002118 epoxides Chemical class 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229940046240 glucomannan Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000002874 hemostatic agent Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 150000002513 isocyanates Chemical class 0.000 claims description 2
- 239000000252 konjac Substances 0.000 claims description 2
- 235000010485 konjac Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000002601 radiography Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims description 2
- 229940125712 tocolytic agent Drugs 0.000 claims description 2
- 239000003675 tocolytic agent Substances 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000005445 natural material Substances 0.000 claims 1
- 239000012812 sealant material Substances 0.000 claims 1
- 229920002994 synthetic fiber Polymers 0.000 claims 1
- 238000001248 thermal gelation Methods 0.000 claims 1
- 230000003195 tocolytic effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 description 19
- 239000000565 sealant Substances 0.000 description 16
- 238000006116 polymerization reaction Methods 0.000 description 15
- 210000004291 uterus Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000007943 implant Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 239000003566 sealing material Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 210000003708 urethra Anatomy 0.000 description 5
- 210000003815 abdominal wall Anatomy 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 238000002669 amniocentesis Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000002706 hydrostatic effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 125000003010 ionic group Chemical group 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 206010036595 Premature delivery Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920013730 reactive polymer Polymers 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical group O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical group CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical group [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/42—Gynaecological or obstetrical instruments or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00491—Surgical glue applicators
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8662498P | 1998-05-23 | 1998-05-23 | |
| US60/086624 | 1998-05-23 | ||
| PCT/US1999/011352 WO1999060938A1 (en) | 1998-05-23 | 1999-05-21 | Method of treatment for premature rupture of membranes in pregnancy (prom) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4094899A AU4094899A (en) | 1999-12-13 |
| AU745302B2 true AU745302B2 (en) | 2002-03-21 |
Family
ID=22199813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU40948/99A Ceased AU745302B2 (en) | 1998-05-23 | 1999-05-21 | Method of treatment for premature rupture of membranes in pregnancy (PROM) |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6350463B1 (enExample) |
| EP (1) | EP1079749A1 (enExample) |
| JP (1) | JP2002516140A (enExample) |
| AU (1) | AU745302B2 (enExample) |
| CA (1) | CA2332978A1 (enExample) |
| WO (1) | WO1999060938A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165193A (en) | 1998-07-06 | 2000-12-26 | Microvention, Inc. | Vascular embolization with an expansible implant |
| US6391047B1 (en) * | 2000-04-18 | 2002-05-21 | David Berry | Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac |
| US7175647B2 (en) * | 2000-04-18 | 2007-02-13 | David Berry | Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac |
| WO2003091350A1 (de) * | 2002-04-24 | 2003-11-06 | Basf Coatings Ag | Carbamat- und/oder allophanatgruppen enthaltende, thermisch härtbare, thixotrope gemische |
| US7497864B2 (en) * | 2003-04-30 | 2009-03-03 | Marctec, Llc. | Tissue fastener and methods for using same |
| US7479112B2 (en) * | 2003-08-26 | 2009-01-20 | Cardiac Pacemakers, Inc. | Acoustic physiological sensor |
| US20050233400A1 (en) * | 2004-03-03 | 2005-10-20 | Weiner Carl P | Proteomic method for predicting success of rescue cerclage |
| US8182647B2 (en) | 2007-07-23 | 2012-05-22 | Cohera Medical, Inc. | Hydrophilic biodegradable adhesives |
| CN101322858B (zh) * | 2008-07-14 | 2013-06-12 | 昆明理工大学 | 一种引导骨组织再生修复的可降解多孔支架材料及其制备方法 |
| EP2328488B1 (en) * | 2008-08-18 | 2018-04-11 | Glenveigh Medical, LLC | Cervical occluder |
| WO2011014631A2 (en) * | 2009-07-30 | 2011-02-03 | Northwestern University | Sealants for membrane repair |
| NZ599524A (en) | 2009-11-09 | 2014-04-30 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
| WO2011057133A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Fragmented hydrogels |
| US10064651B2 (en) | 2012-03-15 | 2018-09-04 | Inpress Technologies, Inc. | Uterine hemorrhage controlling system and method |
| US12076047B2 (en) | 2012-03-15 | 2024-09-03 | Alydia Health, Inc. | Uterine hemorrhage controlling system and method |
| EP2897625B1 (en) * | 2012-09-10 | 2019-10-23 | Wake Forest University Health Sciences | Amniotic membrane and its use in wound healing and tissue engineering constructs |
| US12083245B2 (en) | 2014-10-02 | 2024-09-10 | Wake Forest University Health Sciences | Amniotic membrane powder and its use in wound healing and tissue engineering constructs |
| CA2970831C (en) | 2015-01-10 | 2024-01-09 | Nine Medical, Inc. | Methods and devices to prevent premature birth |
| CN104771778B (zh) * | 2015-03-26 | 2016-10-26 | 昆明理工大学 | 一种微纳米级魔芋葡苷聚糖纤维支架材料的制备方法 |
| SG11201901451WA (en) | 2016-08-24 | 2019-03-28 | Alydia Health Inc | Uterine hemorrhage controlling system and method |
| JP7236378B2 (ja) * | 2017-04-28 | 2023-03-09 | 三洋化成工業株式会社 | 子宮頸管用シーリング剤 |
| US12458399B2 (en) | 2018-12-10 | 2025-11-04 | Alydia Health, Inc. | Postpartum uterine hemorrhage device |
| EP3902506A4 (en) | 2018-12-28 | 2022-09-28 | Nine Medical, Inc. | METHODS AND DEVICES FOR THE PREVENTION OF PREMATURE CHILDREN, STILL CHILDREN, MISSORBORSHIP, INFECTION OR PREGNANCY |
| US20200258426A1 (en) * | 2019-02-08 | 2020-08-13 | Caldera Medical, Inc. | Uterine Model With Pathology |
| CN113171164B (zh) * | 2021-04-13 | 2023-02-17 | 清华大学 | 用于体内原位生物制造的胎膜早破修补装置 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4188951A (en) | 1972-08-17 | 1980-02-19 | Alza Corporation | Intrauterine system embracing selected copolymeric membranes for administering beneficial agent |
| US4007249A (en) * | 1974-07-15 | 1977-02-08 | The Franklin Institute Research Laboratories | Method of forming a removable cervical cap |
| US4128100A (en) * | 1976-10-08 | 1978-12-05 | Wendorff Erwin R | Suture |
| US4100923A (en) * | 1976-12-16 | 1978-07-18 | The Upjohn Company | Extra-amniotic administration device |
| JPS5967969A (ja) | 1982-10-12 | 1984-04-17 | 住友ベークライト株式会社 | 子宮頚管留置カテ−テル |
| US4722730A (en) * | 1986-02-27 | 1988-02-02 | Michael Reese Hospital And Med. Center | Apparatus for relief of fetal distress during labor |
| US5201745A (en) | 1988-03-15 | 1993-04-13 | Imedex | Visceral surgery patch |
| US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
| US5575815A (en) | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
| US5749915A (en) | 1988-08-24 | 1998-05-12 | Focal, Inc. | Polymeric endoluminal paving process |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5283063A (en) | 1992-01-31 | 1994-02-01 | Eagle Vision | Punctum plug method and apparatus |
| US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5469867A (en) | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
| US5749968A (en) | 1993-03-01 | 1998-05-12 | Focal, Inc. | Device for priming for improved adherence of gels to substrates |
| US5800373A (en) | 1995-03-23 | 1998-09-01 | Focal, Inc. | Initiator priming for improved adherence of gels to substrates |
| US5338297A (en) * | 1993-03-19 | 1994-08-16 | Kocur Medical Associates | Cervical canal balloon catheter |
| JP3579052B2 (ja) | 1993-03-23 | 2004-10-20 | フォーカル，インコーポレイテッド | 重合材料の生体組織への局部付与のための装置 |
| US5849035A (en) | 1993-04-28 | 1998-12-15 | Focal, Inc. | Methods for intraluminal photothermoforming |
| US5769091A (en) | 1993-09-20 | 1998-06-23 | Uromed Corporation | Urethral plug having adhesive for enhanced sealing capabilities and method of using said plug |
| US5474065A (en) | 1994-04-04 | 1995-12-12 | Graphic Controls Corporation | Non-invasive fetal probe |
| JPH10505250A (ja) | 1994-06-06 | 1998-05-26 | ケース ウエスターン リザーブ ユニバーシティ | 組織再生のためのバイオマトリックス |
| US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
| US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
| EP1004293A3 (en) | 1994-10-12 | 2001-10-04 | Focal, Inc. | Targeted delivery via biodegradable polymers |
| US5906934A (en) | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
| US5900245A (en) | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5779673A (en) | 1995-06-26 | 1998-07-14 | Focal, Inc. | Devices and methods for application of intraluminal photopolymerized gels |
| US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| US5810721A (en) | 1996-03-04 | 1998-09-22 | Heartport, Inc. | Soft tissue retractor and method for providing surgical access |
| US5863551A (en) | 1996-10-16 | 1999-01-26 | Organogel Canada Ltee | Implantable polymer hydrogel for therapeutic uses |
| US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
-
1999
- 1999-05-21 AU AU40948/99A patent/AU745302B2/en not_active Ceased
- 1999-05-21 US US09/316,879 patent/US6350463B1/en not_active Expired - Fee Related
- 1999-05-21 CA CA002332978A patent/CA2332978A1/en not_active Abandoned
- 1999-05-21 EP EP99924451A patent/EP1079749A1/en not_active Withdrawn
- 1999-05-21 WO PCT/US1999/011352 patent/WO1999060938A1/en not_active Ceased
- 1999-05-21 JP JP2000550406A patent/JP2002516140A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6350463B1 (en) | 2002-02-26 |
| CA2332978A1 (en) | 1999-12-02 |
| EP1079749A1 (en) | 2001-03-07 |
| JP2002516140A (ja) | 2002-06-04 |
| AU4094899A (en) | 1999-12-13 |
| WO1999060938A1 (en) | 1999-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU745302B2 (en) | Method of treatment for premature rupture of membranes in pregnancy (PROM) | |
| US7780980B2 (en) | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels | |
| US20160243272A1 (en) | Surgical adhesive and uses therefore | |
| US12343454B2 (en) | Hydrogels formed in situ and composition design for intrauterine use | |
| JP2010227563A (ja) | 低膨潤性生体適合性ヒドロゲル | |
| JP2010227564A (ja) | 低膨潤性生体適合性ヒドロゲル | |
| BR9711537B1 (pt) | macrâmero polimerizÁvel biodegradÁvel, mÉtodo para aumentar a elasticidade de um gel de polÍmero hidrofÍlico e mÉtodo para melhorar a biodegradabilidade de um macrâmero quimicamente reativo compreendendo carbonato. | |
| JP2008212683A (ja) | 低膨潤性生体適合性ヒドロゲル | |
| US20240100091A1 (en) | Method and kit for treating abnormal hollowed space | |
| US20220142653A1 (en) | Transcervical access systems for intrauterine fluid exchange, such as placement of hydrogels formed in situ | |
| CA2787138C (en) | Composition for producing a temporary intestinal occlusion | |
| Moriarty et al. | Use of FloSeal™ haemostatic gel in massive obstetric haemorrhage: a case report. | |
| US8691245B2 (en) | Composition for forming a temporary obstruction and method of forming the same | |
| RU2283057C1 (ru) | Способ временной эндоскопической обтурации перфорации желудка | |
| CN120529921A (zh) | 利用水凝胶基体的化学组织消融与相关医疗应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ANDRE BIENIARZ Free format text: THE FORMER OWNER WAS: FOCAL, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |